Company Profiles

driven by the PitchBook Platform

Genomas

Genomas
2003 FOUNDED
M&A STATUS
11-50 EMPLOYEES
M&A LATEST DEAL TYPE
$1.75M LATEST DEAL AMOUNT
$5.55M TOTAL AMOUNT RAISED
Description

Developer of personalized medicine platforms to assist physicians in prescribing medications with minimal adverse side effects for a specific group of diseases. The company offers DNA-guided management for the prescribing of drugs for mental illness, pain, heart disease and diabetes. The company's platforms are composed of an ensemble of inherited DNA polymorphisms genotyped by arrays and interpreted by a bioclinical algorithm that convey to physicians the predicted comparisons of side-effect risk and efficacy among drugs for the individual patient.

Website:
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Drug Discovery
Primary Office
67 Jefferson Street
Hartford, CT 06106
United States

+1 (860) 972-4574
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Genomas’s full profile, request a free trial.

Genomas Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Merger/Acquisition 02-Nov-2016 $1.75M $5.55M 00.000 Completed Profitable
10. Secondary Transaction - Private 20-Jul-2016 00000 00.000 Completed Profitable
9. Grant 01-Jun-2011 00.00 00.000 Completed Profitable
8. Grant 15-Sep-2009 00.00 00.000 Completed Profitable
7. Debt - General 09-Apr-2009 00000 00.000 Completed Profitable
6. Grant 19-Mar-2008 00.00 00.000 Completed Profitable
5. Later Stage VC (Series C) 25-Sep-2007 00.00 00.000 000.00 Completed Profitable
4. Grant 24-Jun-2007 00.00 00.000 Completed Profitable
3. Early Stage VC (Series B) 29-Mar-2007 000 00.000 000.00 Completed Profitable
2. Grant 04-Oct-2005 $500k $1.55M Completed Startup
1. Early Stage VC (Series A) 16-Sep-2004 $1.55M $1.55M $8.85M Completed Startup
To view this company’s complete deal history including valuation and funding request access »

Genomas Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series C 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series B 000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A 1,550,000 $0.001000 7% $1 $1 1x $1 9.69%
To view this company’s complete Cap Table request access »

Genomas Executive Team (2)

Name Title Board
Seat
Contact
Info
Gualberto Ruano Ph.D Chief Executive Officer & President
Mohan Kocherla Director, Technical Operations